Israel’s First Port-Based Hepatic Artery Infusion Program: Early Outcomes in Colorectal Liver Metastases
This study demonstrates the feasibility and safety of implementing a new HAI program for carefully selected patients with colorectal liver metastases. Despite the cohort being heavily pretreated with systemic chemotherapy, promising hepatic response rates and disease control rates were observed. These findings support the potential for expanding access to HAI therapy in new geographic regions.
Authors
- Omri Sulimani (ORCID: https://orcid.org/0000-0002-8274-2918)
- Gali Perl
- Nir Wasserberg
- Eran Sadot (ORCID: https://orcid.org/0000-0003-3010-5375)
- Oran Zlotnik (ORCID: https://orcid.org/0000-0002-9965-9432)
- Baruch Brenner (ORCID: https://orcid.org/0000-0002-1596-9362)
- Chen Abitbol
- Nasser Abdul Halim (ORCID: https://orcid.org/0000-0003-4235-1856)
- Shlomit Tamir (ORCID: https://orcid.org/0000-0002-6481-8659)
- Yael Berger (ORCID: https://orcid.org/0000-0003-3396-6584)
- Ana Tovar
- Roy Apel
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1245/s10434-025-17910-9
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Tel Aviv University